Seat­tle Ge­net­ics seeds a new im­muno-on­col­o­gy col­lab­o­ra­tion with the pro­tein ex­plor­ers at Pieris

Seat­tle Ge­net­ics $SGEN be­lieves it could achieve some block­buster can­cer drug work by team­ing up with the pro­tein en­gi­neers at Pieris $PIRS.

The Seat­tle-based biotech is seed­ing a joint dis­cov­ery ef­fort that match­es its suc­cess­ful work on an­ti­body drug con­ju­gates with Pieris’s An­ti­calin plat­form, get­ting the work start­ed with a $30 mil­lion pay­ment.

Should it all work out ac­cord­ing to plan — al­ways a long shot in biotech — Pieris can earn up to $1.2 bil­lion in mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER